Descripción de la Oferta

Fecha límite: 30 de Abril de 2024

Overview
The Clinton Health Access Initiative, Inc. (CHAI) is a global health organization committed to our mission of saving lives and reducing the burden of disease in low-and middle-income countries. We work at the invitation of governments to support them and the private sector to create and sustain high-quality health systems.

CHAI was founded in 2002 in response to the HIV/AIDS epidemic with the goal of dramatically reducing the price of life-saving drugs and increasing access to these medicines in the countries with the highest burden of the disease. Over the following two decades, CHAI has expanded its focus. Today, along with HIV, we work in conjunction with our partners to prevent and treat infectious diseases such as COVID-19, malaria, tuberculosis, and hepatitis. Our work has also expanded into cancer, diabetes, hypertension, and other non-communicable diseases, and we work to accelerate the rollout of lifesaving vaccines, reduce maternal and child mortality, combat chronic malnutrition, and increase access to assistive technology. We are investing in horizontal approaches to strengthen health systems through programs in human resources for health, digital health, and health financing. With each new and innovative program, our strategy is grounded in maximizing sustainable impact at scale, ensuring that governments lead the solutions, that programs are designed to scale nationally, and learnings are shared globally.

At CHAI, our people are our greatest asset, and none of this work would be possible without their talent, time, dedication and passion for our mission and values. We are a highly diverse team of enthusiastic individuals across 40 countries with a broad range of skillsets and life experiences. CHAI is deeply grounded in the countries we work in, with majority of our staff based in program countries. Learn more about our exciting work:

CHAI is an Equal Opportunity Employer, and is committed to providing an environment of fairness, and mutual respect where all applicants have access to equal employment opportunities. CHAI values diversity and inclusion, and recognizes that our mission is best advanced by the leadership and contributions of people with diverse experience, backgrounds, and culture.

CHAI's global malaria & neglected tropical diseases program provides direct technical and operational support to countries around the world to strengthen their vector borne diseases programs and reduce the burden of malaria, dengue, and other neglected tropical diseases (NTDs). We support governments to scale up effective interventions for prevention, diagnosis, treatment, and surveillance, with the goals of sustainably reducing the number of malaria, dengue and NTD-related illnesses and deaths worldwide.

Overview of CHAI's dengue control project

An estimated 50-100 million dengue cases occur each year, claiming >40,000 lives and imposing a global economic burden of $9-$39 billion. Without intervention, this number will continue to escalate due to warming temperatures and urbanization. To date, dengue control efforts have primarily focused on traditional mosquito control measures, such as treating larval habitats and fogging. However, these approaches will be inadequate to address the mounting dengue. Innovative approaches to combat this escalating threat are urgently required.

Wolbachia-based interventions to control dengue and other arboviruses have demonstrated promising efficacy and long-term protection. Certain strains of Wolbachia, a naturally occurring bacteria that infects insects, inhibit viral growth in Aedes aegypti mosquitoes, demonstrating potential for reducing disease transmission. To unlock the global potential of this technology, there is a need to enhance the cost-efficiency of Wolbachia programs. This will involve the establishment of a comprehensive political, funding, and market ecosystem to fac